These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1109 related articles for article (PubMed ID: 30796368)

  • 41. Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology.
    Muinelo-Romay L; Casas-Arozamena C; Abal M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30087246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges and achievements of liquid biopsy technologies employed in early breast cancer.
    Alba-Bernal A; Lavado-Valenzuela R; Domínguez-Recio ME; Jiménez-Rodriguez B; Queipo-Ortuño MI; Alba E; Comino-Méndez I
    EBioMedicine; 2020 Dec; 62():103100. PubMed ID: 33161226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine.
    Tong B; Wang M
    Future Oncol; 2019 Jul; 15(21):2531-2542. PubMed ID: 31339062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cell-free DNA technologies for the analysis of brain cancer.
    Mair R; Mouliere F
    Br J Cancer; 2022 Feb; 126(3):371-378. PubMed ID: 34811503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of liquid biopsies in colorectal cancer.
    Wills B; Gorse E; Lee V
    Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in liquid biopsy-based markers in NSCLC.
    Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
    Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay.
    Alix-Panabières C; Pantel K
    Expert Rev Mol Diagn; 2015; 15(11):1411-7. PubMed ID: 26390240
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Latest advances and perspectives of liquid biopsy for cancer diagnostics driven by microfluidic on-chip assays.
    Xie Y; Xu X; Wang J; Lin J; Ren Y; Wu A
    Lab Chip; 2023 Jun; 23(13):2922-2941. PubMed ID: 37291937
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pre-analytical phase of the liquid biopsy.
    Salvianti F; Gelmini S; Costanza F; Mancini I; Sonnati G; Simi L; Pazzagli M; Pinzani P
    N Biotechnol; 2020 Mar; 55():19-29. PubMed ID: 31580920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.
    Vessies DCL; Schuurbiers MMF; van der Noort V; Schouten I; Linders TC; Lanfermeijer M; Ramkisoensing KL; Hartemink KJ; Monkhorst K; van den Heuvel MM; van den Broek D
    Mol Oncol; 2022 Jul; 16(14):2719-2732. PubMed ID: 35674097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in liquid biopsy approaches for early detection and monitoring of cancer.
    Babayan A; Pantel K
    Genome Med; 2018 Mar; 10(1):21. PubMed ID: 29558971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Liquid biopsy to indvidualise therapy in advanced bladder cancer].
    Junker K
    Aktuelle Urol; 2022 Apr; 53(2):180-187. PubMed ID: 34875700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating tumour cell isolation, analysis and clinical application.
    Zhang X; Xie P; Zhang K; Zhang W
    Cell Oncol (Dordr); 2023 Jun; 46(3):533-544. PubMed ID: 36658417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liquid biopsy of circulating tumor DNA and biosensor applications.
    Li X; Ye M; Zhang W; Tan D; Jaffrezic-Renault N; Yang X; Guo Z
    Biosens Bioelectron; 2019 Feb; 126():596-607. PubMed ID: 30502682
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
    Friend T; Stebbing J
    Br J Cancer; 2021 Sep; 125(7):907-908. PubMed ID: 33953346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular screening of head neck cancer.
    Mali SB
    Oral Oncol; 2023 Sep; 144():106481. PubMed ID: 37399708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
    Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
    Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Minimal residual disease - detection possibilities in haematological and non-haematological malignancies].
    Kalinová M
    Cesk Patol; 2013 Oct; 49(4):131-8. PubMed ID: 24289483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.